Table 2.
UVA Cox models for PFS and OS
| Variable | Category | PFS | OS | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age | <70 y | Reference | Reference | ||
| ≥70 y | 2.07 (1.03, 4.14) | .040 | 1.74 (0.64, 4.71) | .279 | |
| Sex | Female | Reference | Reference | ||
| Male | 0.67 (0.34, 1.33) | .258 | 0.83 (0.32, 2.18) | .712 | |
| Race/ethnicity | Non-Hispanic white | Reference | Reference | ||
| Hispanic white | 1.22 (0.36, 4.13) | .746 | 1.46 (0.29, 7.49) | .648 | |
| African American | 0.32 (0.04, 2.35) | .261 | NE | ||
| Other | 1.19 (0.28, 5.01) | .814 | 1.15 (0.15, 8.91) | .893 | |
| Tumor stage | I-II | Reference | Reference | ||
| III-IV | 1.31 (0.59, 2.88) | .503 | 0.98 (0.35, 2.78) | .970 | |
| B symptoms | No B symptoms | Reference | Reference | ||
| B symptoms | 2.56 (1.25, 5.24) | .010 | 2.35 (0.82, 6.78) | .113 | |
| LDH | Normal LDH | Reference | Reference | ||
| Elevated LDH | 1.10 (0.48, 2.52) | .821 | 1.28 (0.41, 3.98) | .665 | |
| Number of nodal sites | <4 | Reference | Reference | ||
| ≥4 | 1.03 (0.44, 2.38) | .948 | 2.05 (0.69, 6.10) | .197 | |
| Bone marrow involvement | Negative | Reference | Reference | ||
| Positive | 0.57 (0.23, 1.41) | .227 | 0.40 (0.09, 1.80) | .232 | |
| MALT-IPI | 0 | Reference | Reference | ||
| 1 | 1.83 (0.62, 5.43) | .274 | 5.01 (0.65, 38.81) | .123 | |
| 2-3 | 2.36 (0.77, 7.21) | .132 | 3.28 (0.38, 28.34) | .281 | |
| Rituximab maintenance | No | Reference | Reference | ||
| Yes | 0.18 (0.04, 0.79) | .023 | 0.24 (0.03, 1.95) | .184 | |
| Clinical response | Complete response | Reference | Reference | ||
| Noncomplete response | 5.31 (2.63, 10.73) | <.001 | 4.67 (1.71, 12.79) | .003 | |
| Cycles of bendamustine and rituximab | ≥6 | Reference | Reference | ||
| 4-5 | 1.63 (0.69, 3.84) | .268 | 2.24 (0.69, 7.29) | .180 | |
| 1-3 | 2.25 (0.77, 6.56) | .139 | 5.19 (1.60, 16.90) | .006 | |